世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

オンコロジー用マウスモデルの市場調査。北米が世界市場の半分近くを占める


Market Study on Oncology Mice Models: North America Accounts for Nearly Half Global Market Share

オンコロジー・マウスモデル市場 - レポートの範囲 Persistence Market Research社が発行した腫瘍マウスモデル市場に関する最新刊は、機会や現在の市場状況を評価し、市場に影響を与える対応するセクションに... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Persistence Market Research
パーシスタンスマーケットリサーチ
2022年4月13日 US$4,900
シングルユーザーライセンス
ライセンス・価格情報
注文方法はこちら
250 英語

 

サマリー

オンコロジー・マウスモデル市場 - レポートの範囲

Persistence Market Research社が発行した腫瘍マウスモデル市場に関する最新刊は、機会や現在の市場状況を評価し、市場に影響を与える対応するセクションに関する詳細な分析と最新情報を提供しています。この調査は、市場の促進要因、抑制要因、傾向、機会など、現在の市場力学に関する詳細な洞察を提供します。市場調査の主な目的は、市場が2022年から2032年の予測期間中にどのように推移するかについての独占的な情報を提示することです。

市場の成功成長のための重要な指標は、この包括的なレポートで提示されており、市場の前年比(YoY)成長分析、複合年間成長率(CAGR)など、Persistence Market Research社の調査において網羅的に記述されています。この調査研究は、読者が調査期間中の腫瘍マウスモデルの需要や定量的な開発機会を知るための支援となる。

この調査は、投資家、メーカー、サービスプロバイダー、流通業者、サプライヤーなどの景観の株主にとって有益であり、腫瘍マウスモデル市場で繁栄するために適切なビジネス戦略を開発する際に役立ちます。このPersistence Market Researchの調査で示された洞察と情報は、腫瘍マウスモデル市場の株主、業界専門家、投資家、研究者、記者、ビジネス愛好家が活用することが可能である。

市場統計、および腫瘍マウスモデル市場のビジネスシナリオに影響を与えるマクロ経済変数だけでなくミクロ経済変数にリンクされた情報も、現在の研究に含まれています。市場の潜在的な発展に応じて、実質的な洞察も本レポートで遭遇することができます。さらに、このレポートで提出されたデータによって、業界のマイナーな企業や新規参入者は、市場で牽引力を得るために適切な企業選択をする際に支援されることができます。

主要な市場セグメント

Persistence Market Researchの腫瘍マウスモデル市場に関する調査では、製品、エンドユーザー、地域という3つの重要なセグメントに分けられた情報を提供しています。本レポートは、これらのカテゴリに関連する重要な市場力学と成長パラメータに関する包括的なデータと情報を提供しています。

製品

ヒト化免疫系マウスモデル
遺伝子組換え腫瘍マウスモデル
免疫不全マウス
NOGマウスモデル
自然発症腫瘍マウス
その他
エンドユーザー

受託研究機関
製薬会社・バイオファーマ
学術・研究機関
地域別

北アメリカ
ラテンアメリカ
ヨーロッパ
アジア太平洋地域
中東・アフリカ(MEA)
報告書に記載されている主な質問

今後数年間、腫瘍モデルマウスで最も収益性の高い市場を維持し続けるのはどの地域か?
トレンドの変化は市場にどのような影響を与えるのか?
COVID-19危機は市場の成長にどのような影響を与えたか?
市場参加者はどのようにして先進地域の低空飛行の機会を捕らえることができるのか?
市場におけるステークホルダーの戦略はどのようなものですか?
投資家が認識する必要があり、市場への投資中に取り組む可能性がある抑制要因は何か?
市場に影響を与えるであろう開発動向は何か?
腫瘍マウスモデル市場の企業は、先進国および新興国での成長機会をどのように利用することができるのか?
調査方法

Persistence Market Research社の調査では、腫瘍マウスモデル市場の成長に関する広範な調査を実施し、市場の将来の成長パラメータに関する結論を得るために、独自の調査手法を活用しています。この調査手法は、一次調査と二次調査の組み合わせであり、アナリストが結論の正確性と信頼性を確保するのに役立ちます。

市場調査作成時にアナリストが参照した二次資料には、政府機関の統計、業界誌、白書、社内外の独自データベースなどがあります。アナリストは一次資料として、本レポートの作成に貢献したシニアマネージャー、製品ポートフォリオマネージャー、CEO、副社長、マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャーにインタビューを行いました。

一次および二次リソースから取得した包括的な情報は、市場の企業からの検証として機能し、腫瘍マウスモデル市場の成長見通しに関するPersistence Market Research社の予測をより正確で信頼性の高いものにしています

ページTOPに戻る


目次

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions & Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Oncology Drugs – Pipeline Analysis

4.1.1. By Intervention

4.1.2. By Phase

4.1.3. By Funding Authority

4.2. Immuno-Oncology Drugs – Pipeline Analysis

4.2.1. By Phase

4.2.2. By Funding Authority

4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials

4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials

4.5. List of Preclinical CROs

4.6. Parent Market Analysis

4.7. Relative Number of Combination Oncology Therapy Trials

4.8. Landscape of Immuno-Oncology Drug Development

4.9. List of Preclinical immuno-oncology models

4.9.1. Cell lines

4.9.2. Mice Models

4.9.3. Organoids/ spheroids

4.10. Key Regulatory Scenario

4.11. Porter’s Analysis

4.12. PESTLE Analysis

4.13. Supply Chain Analysis

5. Market Background

5.1. Macro-Economic Factors

5.1.1. Global GDP Growth Outlook

5.1.2. Global Healthcare Expenditure

5.2. Forecast Factors - Relevance & Impact

5.2.1. Covid-19 Pandemic

5.2.2. Prevalence of cancer

5.2.3. Rise in R&D investments

5.2.4. Stringent Regulations

5.2.5. Rise in number of pre-clinical and clinical studies

5.2.6. Increasing investment in Cancer research

5.2.7. GDP Growth

5.2.8. Advancements in Models

5.3. Market Dynamics

5.3.1. Drivers

5.3.2. Restraints

5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

6.1. Current COVID19 Statistics and Probable Future Impact

6.2. Current GDP Projection and Probable Impact

6.3. Current Economic Projection as compared to 2008 Economic analysis

6.4. COVID19 and Impact Analysis

6.5. Recovery Scenario – Short term, Midterm, and Long Term Impact

7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

7.1. Historical Market Value (US$ Mn) Analysis, 2017– 2021

7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Product

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017–2021

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022–2032

8.3.1. Humanized Immune System Mice Models

8.3.2. Syngeneic Tumor Mice Models

8.3.3. Immunodeficient Mice Models

8.3.4. NOG Mice Models

8.3.5. Spontaneous Tumor Mice Models

8.3.6. Others

8.4. Market Attractiveness Analysis By Product

9. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by End User

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017–2021

9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032

9.3.1. Contract Research Organizations

9.3.2. Pharma and Biopharma Companies

9.3.3. Academic and Research Institutes

9.4. Market Attractiveness Analysis By Indication

10. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Region

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021

10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032

10.3.1. The North America

10.3.2. Latin America

10.3.3. Europe

10.3.4. Asia Pacific

10.3.5. Middle East and Africa (MEA)

10.4 Market Attractiveness Analysis

11. North America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

11.1. Introduction / Key Findings

11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

11.3.1. By Country

11.3.2. By Product

11.3.3. By End User

11.4. Market Attractiveness Analysis

11.5. Key Market Participants - Intensity Mapping

11.6. Drivers and Restraints - Impact Analysis

12. Latin America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

12.1. Introduction / Key Findings

12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

12.3.1. By Country

12.3.2. By Product

12.3.3. By End User

12.4. Market Attractiveness Analysis

12.5. Key Market Participants - Intensity Mapping

12.6. Drivers and Restraints - Impact Analysis

13. Europe Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

13.1. Introduction / Key Findings

13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

13.3.1. By Country

13.3.2. By Product

13.3.3. By End User

13.4. Market Attractiveness Analysis

13.5. Key Market Participants - Intensity Mapping

13.6. Drivers and Restraints - Impact Analysis

14. Asia Pacific Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

14.1. Introduction / Key Findings

14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

14.3.1. By Country

14.3.2. By Product

14.3.3. By End User

14.4. Market Attractiveness Analysis

14.5. Key Market Participants - Intensity Mapping

14.6. Drivers and Restraints - Impact Analysis

15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

15.1. Introduction / Key Findings

15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

15.3.1. By Country

15.3.2. By Product

15.3.3. By End User

15.4. Market Attractiveness Analysis

15.5. Key Market Participants - Intensity Mapping

15.6. Drivers and Restraints - Impact Analysis

16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032

16.1. Introduction

16.1.1. Market Value Proportion Analysis

16.1.2. Global VS. Country Growth Comparison

16.2. U.S. Medical Cart Market Analysis

16.2.1. By Product

16.2.2. By End User

16.3. Canada Medical Cart Market Analysis

16.3.1. By Product

16.3.2. By End User

16.4. Brazil Medical Cart Market Analysis

16.4.1. By Product

16.4.2. By End User

16.5. Argentina Medical Cart Market Analysis

16.5.1. By Product

16.5.2. By End User

16.6. Mexico Medical Cart Market Analysis

16.6.1. By Product

16.6.2. By End User

16.7. Germany Medical Cart Market Analysis

16.7.1. By Product

16.7.2. By End User

16.8. Italy Medical Cart Market Analysis

16.8.1. By Product

16.8.2. By End User

16.9. France Medical Cart Market Analysis

16.9.1. By Product

16.9.2. By End User

16.10. U.K. Medical Cart Market Analysis

16.10.1. By Product

16.10.2. By End User

16.11. Spain Medical Cart Market Analysis

16.11.1. By Product

16.11.2. By End User

16.12. BENELUX Medical Cart Market Analysis

16.12.1. By Product

16.12.2. By End User

16.13. Russia Medical Cart Market Analysis

16.13.1. By Product

16.13.2. By End User

16.14. China Medical Cart Market Analysis

16.14.1. By Product

16.14.2. By End User

16.15. Japan Medical Cart Market Analysis

16.15.1. By Product

16.15.2. By End User

16.16. India Medical Cart Market Analysis

16.16.1. By Product

16.16.2. By End User

16.17. Australia and New Zealand Medical Cart Market Analysis

16.17.1. By Product

16.17.2. By End User

16.18. GCC Countries Medical Cart Market Analysis

16.18.1. By Product

16.18.2. By End User

16.19. South Africa Medical Cart Market Analysis

16.19.1. By Product

16.19.2. By End User

17. Market Structure Analysis

17.1. Market Analysis by Tier of Companies

17.2. Market Share Analysis of Top Players

18. Competition Analysis

18.1. Competition Benchmarking

18.2. Competition Dashboard

18.3. Competition Deep Dive

18.3.1. The Jackson Laboratory

18.3.1.1. Overview

18.3.1.2. Product Portfolio

18.3.1.3. Key Financials

18.3.1.4. SWOT Analysis

18.3.1.5. Sales Footprint

18.3.1.6. Strategy Overview

18.3.1.6.1. Marketing Strategy

18.3.1.6.2. Product Strategy

18.3.1.6.3. Channel Strategy

18.3.2. Taconic Biosciences

18.3.2.1. Overview

18.3.2.2. Product Portfolio

18.3.2.3. Key Financials

18.3.2.4. SWOT Analysis

18.3.2.5. Sales Footprint

18.3.2.6. Strategy Overview

18.3.2.6.1. Marketing Strategy

18.3.2.6.2. Product Strategy

18.3.2.6.3. Channel Strategy

18.3.3. Charles River Laboratories

18.3.3.1. Overview

18.3.3.2. Product Portfolio

18.3.3.3. Key Financials

18.3.3.4. SWOT Analysis

18.3.3.5. Sales Footprint

18.3.3.6. Strategy Overview

18.3.3.6.1. Marketing Strategy

18.3.3.6.2. Product Strategy

18.3.3.6.3. Channel Strategy

18.3.4. Shanghai Model Organisms Center Inc.

18.3.4.1. Overview

18.3.4.2. Product Portfolio

18.3.4.3. Key Financials

18.3.4.4. SWOT Analysis

18.3.4.5. Sales Footprint

18.3.4.6. Strategy Overview

18.3.4.6.1. Marketing Strategy

18.3.4.6.2. Product Strategy

18.3.4.6.3. Channel Strategy

18.3.5. Envigo

18.3.5.1. Overview

18.3.5.2. Product Portfolio

18.3.5.3. Key Financials

18.3.5.4. SWOT Analysis

18.3.5.5. Sales Footprint

18.3.5.6. Strategy Overview

18.3.5.6.1. Marketing Strategy

18.3.5.6.2. Product Strategy

18.3.5.6.3. Channel Strategy

18.3.6. Biocytogen

18.3.6.1. Overview

18.3.6.2. Product Portfolio

18.3.6.3. Key Financials

18.3.6.4. SWOT Analysis

18.3.6.5. Sales Footprint

18.3.6.6. Strategy Overview

18.3.6.6.1. Marketing Strategy

18.3.6.6.2. Product Strategy

18.3.6.6.3. Channel Strategy

18.3.7. Genoway

18.3.7.1. Overview

18.3.7.2. Product Portfolio

18.3.7.3. Key Financials

18.3.7.4. SWOT Analysis

18.3.7.5. Sales Footprint

18.3.7.6. Strategy Overview

18.3.7.6.1. Marketing Strategy

18.3.7.6.2. Product Strategy

18.3.7.6.3. Channel Strategy

18.3.8. Crown Bioscience Inc. (JSR Corporation).

18.3.8.1. Overview

18.3.8.2. Product Portfolio

18.3.8.3. Key Financials

18.3.8.4. SWOT Analysis

18.3.8.5. Sales Footprint

18.3.8.6. Strategy Overview

18.3.8.6.1. Marketing Strategy

18.3.8.6.2. Product Strategy

18.3.8.6.3. Channel Strategy

18.3.9. Cyagen

18.3.9.1. Overview

18.3.9.2. Product Portfolio

18.3.9.3. Key Financials

18.3.9.4. SWOT Analysis

18.3.9.5. Sales Footprint

18.3.9.6. Strategy Overview

18.3.9.6.1. Marketing Strategy

18.3.9.6.2. Product Strategy

18.3.9.6.3. Channel Strategy

18.3.10. Applied stem cells

18.3.10.1. Overview

18.3.10.2. Product Portfolio

18.3.10.3. Key Financials

18.3.10.4. SWOT Analysis

18.3.10.5. Sales Footprint

18.3.10.6. Strategy Overview

18.3.10.6.1. Marketing Strategy

18.3.10.6.2. Product Strategy

18.3.10.6.3. Channel Strategy

18.3.11. Ingenious Targeting Laboratory

18.3.11.1. Overview

18.3.11.2. Product Portfolio

18.3.11.3. Key Financials

18.3.11.4. SWOT Analysis

18.3.11.5. Sales Footprint

18.3.11.6. Strategy Overview

18.3.11.6.1. Marketing Strategy

18.3.11.6.2. Product Strategy

18.3.11.6.3. Channel Strategy

18.3.12. PolyGene - Transgenic mice model company

18.3.12.1. Overview

18.3.12.2. Product Portfolio

18.3.12.3. Key Financials

18.3.12.4. SWOT Analysis

18.3.12.5. Sales Footprint

18.3.12.6. Strategy Overview

18.3.12.6.1. Marketing Strategy

18.3.12.6.2. Product Strategy

18.3.12.6.3. Channel Strategy

18.3.13. Creative Biolabs

18.3.13.1. Overview

18.3.13.2. Product Portfolio

18.3.13.3. Key Financials

18.3.13.4. SWOT Analysis

18.3.13.5. Sales Footprint

18.3.13.6. Strategy Overview

18.3.13.6.1. Marketing Strategy

18.3.13.6.2. Product Strategy

18.3.13.6.3. Channel Strategy

18.3.14. TransCure Bioservices

18.3.14.1. Overview

18.3.14.2. Product Portfolio

18.3.14.3. Key Financials

18.3.14.4. SWOT Analysis

18.3.14.5. Sales Footprint

18.3.14.6. Strategy Overview

18.3.14.6.1. Marketing Strategy

18.3.14.6.2. Product Strategy

18.3.14.6.3. Channel Strategy

18.3.15. Champions Oncology Inc

18.3.15.1. Overview

18.3.15.2. Product Portfolio

18.3.15.3. Key Financials

18.3.15.4. SWOT Analysis

18.3.15.5. Sales Footprint

18.3.15.6. Strategy Overview

18.3.15.6.1. Marketing Strategy

18.3.15.6.2. Product Strategy

18.3.15.6.3. Channel Strategy

18.3.16. Certis Oncology

18.3.16.1. Overview

18.3.16.2. Product Portfolio

18.3.16.3. Key Financials

18.3.16.4. SWOT Analysis

18.3.16.5. Sales Footprint

18.3.16.6. Strategy Overview

18.3.16.6.1. Marketing Strategy

18.3.16.6.2. Product Strategy

18.3.16.6.3. Channel Strategy

18.3.17. Signature

18.3.17.1. Overview

18.3.17.2. Product Portfolio

18.3.17.3. Key Financials

18.3.17.4. SWOT Analysis

18.3.17.5. Sales Footprint

18.3.17.6. Strategy Overview

18.3.17.6.1. Marketing Strategy

18.3.17.6.2. Product Strategy

18.3.17.6.3. Channel Strategy

18.3.18. Pharmaron

18.3.18.1. Overview

18.3.18.2. Product Portfolio

18.3.18.3. Key Financials

18.3.18.4. SWOT Analysis

18.3.18.5. Sales Footprint

18.3.18.6. Strategy Overview

18.3.18.6.1. Marketing Strategy

18.3.18.6.2. Product Strategy

18.3.18.6.3. Channel Strategy

18.3.19. Laboratory Corporation of America Holdings

18.3.19.1. Overview

18.3.19.2. Product Portfolio

18.3.19.3. Key Financials

18.3.19.4. SWOT Analysis

18.3.19.5. Sales Footprint

18.3.19.6. Strategy Overview

18.3.19.6.1. Marketing Strategy

18.3.19.6.2. Product Strategy

18.3.19.6.3. Channel Strategy

18.3.20. Gempharmatech

18.3.20.1. Overview

18.3.20.2. Product Portfolio

18.3.20.3. Key Financials

18.3.20.4. SWOT Analysis

18.3.20.5. Sales Footprint

18.3.20.6. Strategy Overview

18.3.20.6.1. Marketing Strategy

18.3.20.6.2. Product Strategy

18.3.20.6.3. Channel Strategy

18.3.21. Janvier Labs

18.3.21.1. Overview

18.3.21.2. Product Portfolio

18.3.21.3. Key Financials

18.3.21.4. SWOT Analysis

18.3.21.5. Sales Footprint

18.3.21.6. Strategy Overview

18.3.21.6.1. Marketing Strategy

18.3.21.6.2. Product Strategy

18.3.21.6.3. Channel Strategy

18.3.22. Harbour BioMed

18.3.22.1. Overview

18.3.22.2. Product Portfolio

18.3.22.3. Key Financials

18.3.22.4. SWOT Analysis

18.3.22.5. Sales Footprint

18.3.22.6. Strategy Overview

18.3.22.6.1. Marketing Strategy

18.3.22.6.2. Product Strategy

18.3.22.6.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology


Table 01: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 02: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by End User

Table 03: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Region

Table 04: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 05: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User

Table 06: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 07: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User

Table 08: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 09: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User

Table 10: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 11: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User

Table 12: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 13: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User


Figure 01: Global Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 02: Global Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 03: Global Oncology Mice Models Market Absolute $ Opportunity, 2022-2032

Figure 04: Global Oncology Mice Models Market Share Analysis (%) By Product, 2022 & 2032

Figure 05: Global Oncology Mice Models Market Y-o-Y Growth (%) By Product, 2022- 2032

Figure 06: Global Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 07: Global Oncology Mice Models Market Share Analysis (%) By End User, 2022 & 2032

Figure 08: Global Oncology Mice Models Market Y-o-Y Growth (%) By End User, 2022-2032

Figure 09: Global Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 10: Global Oncology Mice Models Market Share Analysis (%) By Region, 2022 & 2032

Figure 11: Global Oncology Mice Models Market Y-o-Y Growth (%) By Region, 2022-2032

Figure 12: Global Oncology Mice Models Market Attractiveness Analysis, By Region

Figure 13: North America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)

Figure 14: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 15: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 16: North America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 17: North America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 18: North America Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 19: North America Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 20: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)

Figure 21: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 22: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 23: Latin America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 24: Latin America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 25: Latin America Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 26: Latin America Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 27: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)

Figure 28: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 29: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 30: Europe Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 31: Europe Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 32: Europe Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 33: Europe Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 35: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 36: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 37: Asia Pacific Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 38: Asia Pacific Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 39: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 40: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 41: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)

Figure 42: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 43: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 44: Middle East and Africa (MEA) Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 45: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 46: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 47: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 48: U.S. Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 49: U.S. Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 50: Canada Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 51: Canada Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 52: Mexico Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 53: Mexico Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 54: Brazil Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 55: Brazil Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 56: India Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 57: India Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 58: China Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 59: China Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 60: Japan Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 61: Japan Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 62: Germany Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 63: Germany Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 64: France Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 65: France Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 66: Italy Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 67: Italy Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 68: Russia Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 69: Russia Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 70: GCC Countries Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 71: GCC Countries Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 72: South Africa Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 73: South Africa Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

 

ページTOPに戻る


 

Summary

Oncology Mice Models Market - Scope of Report

The latest publication by Persistence Market Research on the oncology mice models market evaluates the opportunities and current market landscape and provides detailed analysis and updates about corresponding sections affecting the market. The study offers detailed insights on current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2022-2032.

Important indicators for the successful growth of the market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for oncology mice models and the quantitative development opportunities during the study period.

The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the oncology mice models market. The insights and information presented in this Persistence Market Research study can be leveraged by shareholders in the oncology mice models market, industry experts, investors, researchers, and reporters, as well as business enthusiasts.

Market statistics, as well as information linked to the macro- as well as micro-economic variables affecting the business scenario in the oncology mice models market are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.

Key Market Segments

Persistence Market Research’s study on the oncology mice models market offers information divided into three important segments — product, end user, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categories.

Product

Humanized Immune System Mice Models
Syngeneic Tumor Mice Models
Immunodeficient Mice Models
NOG Mice Models
Spontaneous Tumor Mice Models
Others
End User

Contract Research Organizations
Pharma and Biopharma Companies
Academic and Research Institutes
Region

North America
Latin America
Europe
Asia Pacific
Middle East and Africa (MEA)
Key Questions Answered in Report

Which regions will continue to remain the most profitable markets for oncology mice models over the coming years?
How will changing trends impact the market?
How has the COVID-19 crisis impacted market growth?
How can market players capture the low-hanging opportunities in developed regions?
What are the strategies of stakeholders in the market to shape their position in this landscape?
What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
What are the developmental trends that will impact the market?
How can companies in the oncology mice models market avail themselves the growth opportunities in developed and emerging sectors?
Research Methodology

In Persistence Market Research’s study, a unique research methodology is utilized to conduct extensive research on the growth of the oncology mice models market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts ensure the accuracy and reliability of the conclusions.

Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.

Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research’s projections on the growth prospects of the oncology mice models market more accurate and reliable



ページTOPに戻る


Table of Contents

1. Executive Summary

1.1. Global Market Outlook

1.2. Demand Side Trends

1.3. Supply Side Trends

1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy

2.2. Market Definition / Scope / Limitations

2.3. Inclusions & Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market

3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Oncology Drugs – Pipeline Analysis

4.1.1. By Intervention

4.1.2. By Phase

4.1.3. By Funding Authority

4.2. Immuno-Oncology Drugs – Pipeline Analysis

4.2.1. By Phase

4.2.2. By Funding Authority

4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials

4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials

4.5. List of Preclinical CROs

4.6. Parent Market Analysis

4.7. Relative Number of Combination Oncology Therapy Trials

4.8. Landscape of Immuno-Oncology Drug Development

4.9. List of Preclinical immuno-oncology models

4.9.1. Cell lines

4.9.2. Mice Models

4.9.3. Organoids/ spheroids

4.10. Key Regulatory Scenario

4.11. Porter’s Analysis

4.12. PESTLE Analysis

4.13. Supply Chain Analysis

5. Market Background

5.1. Macro-Economic Factors

5.1.1. Global GDP Growth Outlook

5.1.2. Global Healthcare Expenditure

5.2. Forecast Factors - Relevance & Impact

5.2.1. Covid-19 Pandemic

5.2.2. Prevalence of cancer

5.2.3. Rise in R&D investments

5.2.4. Stringent Regulations

5.2.5. Rise in number of pre-clinical and clinical studies

5.2.6. Increasing investment in Cancer research

5.2.7. GDP Growth

5.2.8. Advancements in Models

5.3. Market Dynamics

5.3.1. Drivers

5.3.2. Restraints

5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

6.1. Current COVID19 Statistics and Probable Future Impact

6.2. Current GDP Projection and Probable Impact

6.3. Current Economic Projection as compared to 2008 Economic analysis

6.4. COVID19 and Impact Analysis

6.5. Recovery Scenario – Short term, Midterm, and Long Term Impact

7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2017–2021 and Forecast, 2022–2032

7.1. Historical Market Value (US$ Mn) Analysis, 2017– 2021

7.2. Current and Future Market Value (US$ Mn) Projections, 2022–2032

7.2.1. Y-o-Y Growth Trend Analysis

7.2.2. Absolute $ Opportunity Analysis

8. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Product

8.1. Introduction / Key Findings

8.2. Historical Market Size (US$ Mn) Analysis By Product, 2017–2021

8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2022–2032

8.3.1. Humanized Immune System Mice Models

8.3.2. Syngeneic Tumor Mice Models

8.3.3. Immunodeficient Mice Models

8.3.4. NOG Mice Models

8.3.5. Spontaneous Tumor Mice Models

8.3.6. Others

8.4. Market Attractiveness Analysis By Product

9. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by End User

9.1. Introduction / Key Findings

9.2. Historical Market Size (US$ Mn) Analysis By End User, 2017–2021

9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2022–2032

9.3.1. Contract Research Organizations

9.3.2. Pharma and Biopharma Companies

9.3.3. Academic and Research Institutes

9.4. Market Attractiveness Analysis By Indication

10. Global Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032, by Region

10.1. Introduction / Key Findings

10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017–2021

10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2022–2032

10.3.1. The North America

10.3.2. Latin America

10.3.3. Europe

10.3.4. Asia Pacific

10.3.5. Middle East and Africa (MEA)

10.4 Market Attractiveness Analysis

11. North America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

11.1. Introduction / Key Findings

11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

11.3.1. By Country

11.3.2. By Product

11.3.3. By End User

11.4. Market Attractiveness Analysis

11.5. Key Market Participants - Intensity Mapping

11.6. Drivers and Restraints - Impact Analysis

12. Latin America Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

12.1. Introduction / Key Findings

12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

12.3.1. By Country

12.3.2. By Product

12.3.3. By End User

12.4. Market Attractiveness Analysis

12.5. Key Market Participants - Intensity Mapping

12.6. Drivers and Restraints - Impact Analysis

13. Europe Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

13.1. Introduction / Key Findings

13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

13.3.1. By Country

13.3.2. By Product

13.3.3. By End User

13.4. Market Attractiveness Analysis

13.5. Key Market Participants - Intensity Mapping

13.6. Drivers and Restraints - Impact Analysis

14. Asia Pacific Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

14.1. Introduction / Key Findings

14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

14.3.1. By Country

14.3.2. By Product

14.3.3. By End User

14.4. Market Attractiveness Analysis

14.5. Key Market Participants - Intensity Mapping

14.6. Drivers and Restraints - Impact Analysis

15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2017–2021 and Forecast 2022–2032

15.1. Introduction / Key Findings

15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2017–2021

15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022–2032

15.3.1. By Country

15.3.2. By Product

15.3.3. By End User

15.4. Market Attractiveness Analysis

15.5. Key Market Participants - Intensity Mapping

15.6. Drivers and Restraints - Impact Analysis

16. Country Level Medical Cart Market Analysis and Forecast 2022 & 2032

16.1. Introduction

16.1.1. Market Value Proportion Analysis

16.1.2. Global VS. Country Growth Comparison

16.2. U.S. Medical Cart Market Analysis

16.2.1. By Product

16.2.2. By End User

16.3. Canada Medical Cart Market Analysis

16.3.1. By Product

16.3.2. By End User

16.4. Brazil Medical Cart Market Analysis

16.4.1. By Product

16.4.2. By End User

16.5. Argentina Medical Cart Market Analysis

16.5.1. By Product

16.5.2. By End User

16.6. Mexico Medical Cart Market Analysis

16.6.1. By Product

16.6.2. By End User

16.7. Germany Medical Cart Market Analysis

16.7.1. By Product

16.7.2. By End User

16.8. Italy Medical Cart Market Analysis

16.8.1. By Product

16.8.2. By End User

16.9. France Medical Cart Market Analysis

16.9.1. By Product

16.9.2. By End User

16.10. U.K. Medical Cart Market Analysis

16.10.1. By Product

16.10.2. By End User

16.11. Spain Medical Cart Market Analysis

16.11.1. By Product

16.11.2. By End User

16.12. BENELUX Medical Cart Market Analysis

16.12.1. By Product

16.12.2. By End User

16.13. Russia Medical Cart Market Analysis

16.13.1. By Product

16.13.2. By End User

16.14. China Medical Cart Market Analysis

16.14.1. By Product

16.14.2. By End User

16.15. Japan Medical Cart Market Analysis

16.15.1. By Product

16.15.2. By End User

16.16. India Medical Cart Market Analysis

16.16.1. By Product

16.16.2. By End User

16.17. Australia and New Zealand Medical Cart Market Analysis

16.17.1. By Product

16.17.2. By End User

16.18. GCC Countries Medical Cart Market Analysis

16.18.1. By Product

16.18.2. By End User

16.19. South Africa Medical Cart Market Analysis

16.19.1. By Product

16.19.2. By End User

17. Market Structure Analysis

17.1. Market Analysis by Tier of Companies

17.2. Market Share Analysis of Top Players

18. Competition Analysis

18.1. Competition Benchmarking

18.2. Competition Dashboard

18.3. Competition Deep Dive

18.3.1. The Jackson Laboratory

18.3.1.1. Overview

18.3.1.2. Product Portfolio

18.3.1.3. Key Financials

18.3.1.4. SWOT Analysis

18.3.1.5. Sales Footprint

18.3.1.6. Strategy Overview

18.3.1.6.1. Marketing Strategy

18.3.1.6.2. Product Strategy

18.3.1.6.3. Channel Strategy

18.3.2. Taconic Biosciences

18.3.2.1. Overview

18.3.2.2. Product Portfolio

18.3.2.3. Key Financials

18.3.2.4. SWOT Analysis

18.3.2.5. Sales Footprint

18.3.2.6. Strategy Overview

18.3.2.6.1. Marketing Strategy

18.3.2.6.2. Product Strategy

18.3.2.6.3. Channel Strategy

18.3.3. Charles River Laboratories

18.3.3.1. Overview

18.3.3.2. Product Portfolio

18.3.3.3. Key Financials

18.3.3.4. SWOT Analysis

18.3.3.5. Sales Footprint

18.3.3.6. Strategy Overview

18.3.3.6.1. Marketing Strategy

18.3.3.6.2. Product Strategy

18.3.3.6.3. Channel Strategy

18.3.4. Shanghai Model Organisms Center Inc.

18.3.4.1. Overview

18.3.4.2. Product Portfolio

18.3.4.3. Key Financials

18.3.4.4. SWOT Analysis

18.3.4.5. Sales Footprint

18.3.4.6. Strategy Overview

18.3.4.6.1. Marketing Strategy

18.3.4.6.2. Product Strategy

18.3.4.6.3. Channel Strategy

18.3.5. Envigo

18.3.5.1. Overview

18.3.5.2. Product Portfolio

18.3.5.3. Key Financials

18.3.5.4. SWOT Analysis

18.3.5.5. Sales Footprint

18.3.5.6. Strategy Overview

18.3.5.6.1. Marketing Strategy

18.3.5.6.2. Product Strategy

18.3.5.6.3. Channel Strategy

18.3.6. Biocytogen

18.3.6.1. Overview

18.3.6.2. Product Portfolio

18.3.6.3. Key Financials

18.3.6.4. SWOT Analysis

18.3.6.5. Sales Footprint

18.3.6.6. Strategy Overview

18.3.6.6.1. Marketing Strategy

18.3.6.6.2. Product Strategy

18.3.6.6.3. Channel Strategy

18.3.7. Genoway

18.3.7.1. Overview

18.3.7.2. Product Portfolio

18.3.7.3. Key Financials

18.3.7.4. SWOT Analysis

18.3.7.5. Sales Footprint

18.3.7.6. Strategy Overview

18.3.7.6.1. Marketing Strategy

18.3.7.6.2. Product Strategy

18.3.7.6.3. Channel Strategy

18.3.8. Crown Bioscience Inc. (JSR Corporation).

18.3.8.1. Overview

18.3.8.2. Product Portfolio

18.3.8.3. Key Financials

18.3.8.4. SWOT Analysis

18.3.8.5. Sales Footprint

18.3.8.6. Strategy Overview

18.3.8.6.1. Marketing Strategy

18.3.8.6.2. Product Strategy

18.3.8.6.3. Channel Strategy

18.3.9. Cyagen

18.3.9.1. Overview

18.3.9.2. Product Portfolio

18.3.9.3. Key Financials

18.3.9.4. SWOT Analysis

18.3.9.5. Sales Footprint

18.3.9.6. Strategy Overview

18.3.9.6.1. Marketing Strategy

18.3.9.6.2. Product Strategy

18.3.9.6.3. Channel Strategy

18.3.10. Applied stem cells

18.3.10.1. Overview

18.3.10.2. Product Portfolio

18.3.10.3. Key Financials

18.3.10.4. SWOT Analysis

18.3.10.5. Sales Footprint

18.3.10.6. Strategy Overview

18.3.10.6.1. Marketing Strategy

18.3.10.6.2. Product Strategy

18.3.10.6.3. Channel Strategy

18.3.11. Ingenious Targeting Laboratory

18.3.11.1. Overview

18.3.11.2. Product Portfolio

18.3.11.3. Key Financials

18.3.11.4. SWOT Analysis

18.3.11.5. Sales Footprint

18.3.11.6. Strategy Overview

18.3.11.6.1. Marketing Strategy

18.3.11.6.2. Product Strategy

18.3.11.6.3. Channel Strategy

18.3.12. PolyGene - Transgenic mice model company

18.3.12.1. Overview

18.3.12.2. Product Portfolio

18.3.12.3. Key Financials

18.3.12.4. SWOT Analysis

18.3.12.5. Sales Footprint

18.3.12.6. Strategy Overview

18.3.12.6.1. Marketing Strategy

18.3.12.6.2. Product Strategy

18.3.12.6.3. Channel Strategy

18.3.13. Creative Biolabs

18.3.13.1. Overview

18.3.13.2. Product Portfolio

18.3.13.3. Key Financials

18.3.13.4. SWOT Analysis

18.3.13.5. Sales Footprint

18.3.13.6. Strategy Overview

18.3.13.6.1. Marketing Strategy

18.3.13.6.2. Product Strategy

18.3.13.6.3. Channel Strategy

18.3.14. TransCure Bioservices

18.3.14.1. Overview

18.3.14.2. Product Portfolio

18.3.14.3. Key Financials

18.3.14.4. SWOT Analysis

18.3.14.5. Sales Footprint

18.3.14.6. Strategy Overview

18.3.14.6.1. Marketing Strategy

18.3.14.6.2. Product Strategy

18.3.14.6.3. Channel Strategy

18.3.15. Champions Oncology Inc

18.3.15.1. Overview

18.3.15.2. Product Portfolio

18.3.15.3. Key Financials

18.3.15.4. SWOT Analysis

18.3.15.5. Sales Footprint

18.3.15.6. Strategy Overview

18.3.15.6.1. Marketing Strategy

18.3.15.6.2. Product Strategy

18.3.15.6.3. Channel Strategy

18.3.16. Certis Oncology

18.3.16.1. Overview

18.3.16.2. Product Portfolio

18.3.16.3. Key Financials

18.3.16.4. SWOT Analysis

18.3.16.5. Sales Footprint

18.3.16.6. Strategy Overview

18.3.16.6.1. Marketing Strategy

18.3.16.6.2. Product Strategy

18.3.16.6.3. Channel Strategy

18.3.17. Signature

18.3.17.1. Overview

18.3.17.2. Product Portfolio

18.3.17.3. Key Financials

18.3.17.4. SWOT Analysis

18.3.17.5. Sales Footprint

18.3.17.6. Strategy Overview

18.3.17.6.1. Marketing Strategy

18.3.17.6.2. Product Strategy

18.3.17.6.3. Channel Strategy

18.3.18. Pharmaron

18.3.18.1. Overview

18.3.18.2. Product Portfolio

18.3.18.3. Key Financials

18.3.18.4. SWOT Analysis

18.3.18.5. Sales Footprint

18.3.18.6. Strategy Overview

18.3.18.6.1. Marketing Strategy

18.3.18.6.2. Product Strategy

18.3.18.6.3. Channel Strategy

18.3.19. Laboratory Corporation of America Holdings

18.3.19.1. Overview

18.3.19.2. Product Portfolio

18.3.19.3. Key Financials

18.3.19.4. SWOT Analysis

18.3.19.5. Sales Footprint

18.3.19.6. Strategy Overview

18.3.19.6.1. Marketing Strategy

18.3.19.6.2. Product Strategy

18.3.19.6.3. Channel Strategy

18.3.20. Gempharmatech

18.3.20.1. Overview

18.3.20.2. Product Portfolio

18.3.20.3. Key Financials

18.3.20.4. SWOT Analysis

18.3.20.5. Sales Footprint

18.3.20.6. Strategy Overview

18.3.20.6.1. Marketing Strategy

18.3.20.6.2. Product Strategy

18.3.20.6.3. Channel Strategy

18.3.21. Janvier Labs

18.3.21.1. Overview

18.3.21.2. Product Portfolio

18.3.21.3. Key Financials

18.3.21.4. SWOT Analysis

18.3.21.5. Sales Footprint

18.3.21.6. Strategy Overview

18.3.21.6.1. Marketing Strategy

18.3.21.6.2. Product Strategy

18.3.21.6.3. Channel Strategy

18.3.22. Harbour BioMed

18.3.22.1. Overview

18.3.22.2. Product Portfolio

18.3.22.3. Key Financials

18.3.22.4. SWOT Analysis

18.3.22.5. Sales Footprint

18.3.22.6. Strategy Overview

18.3.22.6.1. Marketing Strategy

18.3.22.6.2. Product Strategy

18.3.22.6.3. Channel Strategy

19. Assumptions and Acronyms Used

20. Research Methodology


Table 01: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 02: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by End User

Table 03: Global Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Region

Table 04: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 05: North America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User

Table 06: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 07: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User

Table 08: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 09: Europe Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User

Table 10: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 11: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User

Table 12: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, by Product

Table 13: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis 2017–2021 and Forecast 2022-2032, By End User


Figure 01: Global Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 02: Global Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 03: Global Oncology Mice Models Market Absolute $ Opportunity, 2022-2032

Figure 04: Global Oncology Mice Models Market Share Analysis (%) By Product, 2022 & 2032

Figure 05: Global Oncology Mice Models Market Y-o-Y Growth (%) By Product, 2022- 2032

Figure 06: Global Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 07: Global Oncology Mice Models Market Share Analysis (%) By End User, 2022 & 2032

Figure 08: Global Oncology Mice Models Market Y-o-Y Growth (%) By End User, 2022-2032

Figure 09: Global Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 10: Global Oncology Mice Models Market Share Analysis (%) By Region, 2022 & 2032

Figure 11: Global Oncology Mice Models Market Y-o-Y Growth (%) By Region, 2022-2032

Figure 12: Global Oncology Mice Models Market Attractiveness Analysis, By Region

Figure 13: North America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)

Figure 14: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 15: North America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 16: North America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 17: North America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 18: North America Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 19: North America Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 20: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)

Figure 21: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 22: Latin America Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 23: Latin America Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 24: Latin America Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 25: Latin America Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 26: Latin America Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 27: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)

Figure 28: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 29: Europe Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 30: Europe Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 31: Europe Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 32: Europe Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 33: Europe Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 35: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 36: Asia Pacific Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 37: Asia Pacific Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 38: Asia Pacific Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 39: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 40: Asia Pacific Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 41: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, 2021 (A), 2026 (F) & 2032 (F)

Figure 42: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by Product, 2022

Figure 43: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$ Mn) Analysis, by End User, 2022

Figure 44: Middle East and Africa (MEA) Oncology Mice Models Historical Market (US$ Mn) Analysis, 2017–2021

Figure 45: Middle East and Africa (MEA) Oncology Mice Models Market Value (US$) & Y-o-Y Growth (%), 2022-2032

Figure 46: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By Product

Figure 47: Middle East and Africa (MEA) Oncology Mice Models Market Attractiveness Analysis, By End User

Figure 48: U.S. Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 49: U.S. Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 50: Canada Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 51: Canada Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 52: Mexico Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 53: Mexico Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 54: Brazil Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 55: Brazil Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 56: India Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 57: India Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 58: China Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 59: China Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 60: Japan Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 61: Japan Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 62: Germany Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 63: Germany Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 64: France Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 65: France Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 66: Italy Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 67: Italy Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 68: Russia Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 69: Russia Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 70: GCC Countries Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 71: GCC Countries Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

Figure 72: South Africa Oncology Mice Models Market Share Analysis (%) By Product, 2021 & 2032

Figure 73: South Africa Oncology Mice Models Market Share Analysis (%) By End User, 2021 & 2032

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(バイオ薬物)の最新刊レポート

本レポートと同じKEY WORD(oncology)の最新刊レポート


よくあるご質問


Persistence Market Research社はどのような調査会社ですか?


パーシスタンスマーケットリサーチ(Persistence Market Research/PMR)は独自の方法論を用いたデータ解析と市場調査をベースに広範な産業調査報告書とカスタム調査を提供しています... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/07 10:27

155.63 円

167.26 円

203.27 円

ページTOPに戻る